PHARMExcel has been recognised by Medline Review as a catalyst for purpose-driven innovation in Phase I/II oncology studies. As the global cancer burden constantly increases, there is a distinct need to innovate to bring therapies to patients faster. PHARMExcel believes that it has an important role to play in the fight against cancer: Striving to provide end-to-end oncology clinical trial support that empowers academic sponsors, university spinouts, and emerging biotechs to turn complex oncology ideas into next-generation oncology breakthroughs. This Top Oncology CRO does this by treating every study as a responsibility: to the science, the sponsor, and ultimately, the patients whose lives may be transformed, rather than treating a trial as a project.
PHARMExcel specialises in Phase I, Phase II, first-in-human oncology studies and is experienced in clinical trials involving new therapeutic areas like immuno-oncology, gene therapy, radiopharmaceuticals and rare cancer indications. The CRO provides an operational ecosystem for its clients, with infrastructure that is purpose-built for the demands of oncology clinical trials, including regulations and sensitive nuances.
PHARMExcel Founder and CEO Yvanne Enever said of the Medline Review recognition: “The advancement in oncology science and treatments is incredibly inspiring. We are honoured to be involved in progressing next-generation oncology therapies. Being named as a Top Oncology Solution Provider is a significant achievement, which we are very proud of”.
PHARMExcel’s dedication to advancing oncology treatment is perhaps best demonstrated by some of the landmark clinical trials that the CRO has been involved in. Firstly, the LAUREL trial, a first-in-human study exploring NK cell therapy for patients with Myelodysplastic Syndrome (MDS) with excess blasts (MDS-EB-1/2 -MDS-CMML 1/2/2) or with acute myeloid leukaemia (AML). PHARMExcel provided full-service support, from study start up and regulatory approvals to vendor management and NHS site coordination. Its approach made it possible for the study to proceed efficiently and with regulatory alignment. This study demonstrated PHARMExcel’s ability to deliver at the cutting edge of oncology science. In addition, it shows the CRO’s experience at testing clinical viability, which is central to delivering innovative oncology treatment.
Another landmark clinical trial that PHARMExcel was involved in was the TRALA study, which investigated a radiolabelled monoclonal antibody treatment for AL-Amyloidosis. PHARMExcel navigated a highly complex trial environment involving radiopharmaceuticals and rare cancer indications. The team’s seamless execution, attention to safety protocols, and coordination of multiple sites underscored their ability to manage niche studies with high degrees of complexity.
PHARMExcel’s human approach and the fact that the organisation is driven by its values are aspects that set it apart. PHARMExcel describes itself as high-touch, detail-driven, and always focused on the patient that will ultimately benefit. According to PHARMExcel CEO Yvanne Enever: “For us, it’s never just about ticking boxes or delivering data. It’s about knowing that what we do could help bring a life-saving treatment to someone who really needs it. That’s the bigger picture we’re always working toward, helping innovation reach the people it’s meant to help.”
Beyond this and perhaps what defines PHARMExcel as an excellent oncology service provider, is the makeup of its team, which is composed of individuals with strong NHS clinical and academic backgrounds. Basing trial development, oversight and management on their deep understanding of the therapeutic area and the context in which care will be delivered brings an insider’s perspective to their clinical trials. The PHARMExcel team incorporates clinical insights into every aspect of their work, from understanding the real-world constraints of NHS research delivery to anticipating the needs of investigators and patients. This additional, deep and relevant experience is an invaluable asset to the academic institutions, spin-outs and public health bodies that PHARMExcel typically supports.
Groundbreaking science and innovative oncology research are bringing hope to patients and their families. Knowing that oncology innovation and research is being supported by purpose driven organisations like PHARMExcel, that consciously apply their expertise and care to bring the most effective treatments from the research bench to the patient’s bedside, should give us all some peace of mind.
PHARMExcel reports data for rare disease trials across 5 technologies
ATMP Oncology Study: The first-in man trial for a Biotech’s novel therapy to prime the patient’s natural killer cells to attack their cancer
PHARMExcel named finalist for Most Impactful CRO of the Year at OBN Awards
How PHARMExcel collaborated with ECMC to deliver a new revolutionary radiation therapy
